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| INTRODUCTION
Vitamin K antagonists (VKA) are frequently prescribed oral anticoagulants and are effective in the treatment and prevention of venous and arterial thromboembolic diseases. 1 An important complication of VKA treatment is the occurrence of bleeding events, which typically involve the gastrointestinal system, central nervous system, or soft tissues.
2
The annual incidence rate of major bleeding episodes in VKA treated patients is 1-3%. [3] [4] [5] [6] Life-threatening bleeding occurs in approximately 0.25% of patients annually.
4
Patients with severe VKA-associated bleeding require immediate restoration of haemostasis by reversing the anticoagulant effect of VKA as part of the bleeding management. 1 The first step in reversal is usually vitamin K administration. 7, 8 Intravenously administered vitamin K normalizes the international normalized ratio (INR) within 12-16 hours, 9 whereas oral administration of vitamin K will take up to 24 hours to take effect. 10 Since immediate reversal is indicated in these patients, several international treatment guidelines recommend the use of prothrombin complex concentrate (PCC). 1, 11, 12 Three-factor PCC contains the vitamin K-dependant coagulation factors II, IX, and X, and protein C and S. Four-factor prothrombin complex concentrate (PCC) additionally contains factor VII. 13, 14 PCC products are highly effective in normalizing INR. 3, 15 Advantages of PCC over substitution with fresh frozen plasma (FFP) are a smaller volume and shorter duration of infusion and a low pathogen transmission risk. 16 In the Netherlands, PCC has been widely available for decades in all national hospitals and there is ample experience with its use in patients with bleeding or in those that need to undergo emergency invasive procedures.
In 2013, a new standard was introduced to evaluate haemostatic efficacy of reversal agents in bleeding complications related to anticoagulant use. 17 This classification scheme was developed in collaboration with the Food and Drug Administration (FDA) for a randomized controlled trial (RCT) comparing Beriplex (PCC) with FFP. 17 In the current studies testing antidotes for the direct oral anticoagulants, 18, 19 this classification scheme is standardly used to assess haemostatic efficacy of the reversal agent. Both the FDA and the European Medicines Agency (EMA) have accepted this standard for ongoing and future studies. This endpoint was not used previously in studies of reversing VKA in the setting of haemorrhage. Therefore, the current study addressed this endpoint in order to provide comparison to the results of ongoing studies of antidotes to DOACs. The aim of this cohort study was to evaluate clinical outcome parameters, including haemostatic efficacy, thromboembolic complications, and mortality in patients treated with PCC for VKA-associated bleeding complications.
| METHODS

| Study design and study population
We performed a retrospective cohort study of consecutive patients who received PCC for a VKA-associated bleeding between September • Cohort study of patients with VKA bleeds treated with prothrombin complex concentrate (PCC).
• Effective haemostasis was achieved in 68% of patients with a VKA-associated bleeding.
• Thromboembolism rates were low and mortality rates high at 30 days after PCC administration. 
| Clinical presentation and course
Bleeding events were classified as major or minor bleeding. Major bleeding was defined according to the ISTH criteria as clinically overt and causing a decrease in haemoglobin of ≥2 grams per decilitre or requiring two or more units of packed cells or whole blood, occurring in a critical organ or site, or being fatal. 20 All other bleedings were considered minor bleedings.
All major bleeding events were classified using two classification schemes that were developed and published previously. [21] [22] [23] The first classification was used to assess the severity of the major bleeding event at presentation (Table S2A ). The second classification was used to assess the applied procedures and interventions for treatment and the clinical outcome of the bleeding event (Table S2B ). Both classification schemes consist of four different categories, with one being the mildest and four the most severe. 
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| Statistical analysis
| RESULTS
| Study population
Demographic and clinical characteristics of the 100 patients with a VKA-associated bleeding event treated with PCC at presentation are detailed in Table 1 . The mean age was 74 ± 12 years and 54 (54%) of the patients were male. There were no significant differences in age, sex, or weight between the five centers. Almost three-quarters of the study population had a history of hypertension (71%) and approximately one-quarter had as history of type 2 diabetes mellitus (24%).
Antiplatelet drugs were used in 17 (17%) of patients; of whom seven patients clopidogrel and six aspirin.
T A B L E 1 Demographics and characteristics of patients with a VKA-associated bleeding event
Total patients N = 100
Age in years, mean (SD) 74.4 ± 11.6
Male sex, n (%) 54 ( (36%) patients with a GI bleeding. The mean age of patients with an ICH was 72 ± 12 years and 49% of them were male. The 36 patients with GI bleeding had a mean age of 76 ± 11 years and 67% were male. When combining the other types of bleeding (n = 23), the mean age was 75 ± 12 years and 44%
were male. The distribution of bleeding types differed significantly between the five centers (p = .01); two centers included predominantly ICH, two included mostly GI bleeds, and one included a variety of bleeding types.
| Treatment of VKA-related bleedings
The median dose of administered PCC was 2000 international units an endoscopic, and in three (8%) a radiological procedure was performed (Table 2 ).
| Outcome parameters
| Haemostatic efficacy
Assessment of the adapted classification of haemostatic efficacy showed that effective haemostasis was achieved in 67 (68%) of 98 patients; 31 (31%) of 98 had non-effective or poor haemostasis, and for two patients effective haemostasis could not be assessed primarily or using the surrogate efficacy outcome measurement (Table 3 ).
Using the Sarode criteria for haemostatic efficacy, 17 assessment was possible in 66/100 patients. In 34 (34%) patients the rating was missing, mostly due to the absence of repeat CT scans for ICH. Effective haemostasis was achieved in 47 (71%) of 66 evaluable patients (Table 3) .
Stratification by type of bleeding showed that in nine (22%) of 41 patients with an ICH the haemostatic efficacy could be assessed using 
T A B L E 2 Treatment of VKA-associated bleeding events
In the 36 patients presenting with GI bleeding, 20 (56%) had excellent haemostatic efficacy, nine good, six poor and in one patient the rating was not assessable.
| INR correction
At presentation, the median INR was 3.85 with an interquartile range INR measurement at 24 hours after PCC infusion was performed in 77 patients and the median INR value was 1.3 (IQR 1.1-1.6).
| Safety outcomes
Thromboembolic complications were reported in 5 (5%) patients (Table 4) . Four of these were venous thromboembolic events.
Eleven (11%) patients had a new bleeding complication within 30 days after the VKA associated bleeding event. Most of these were re-bleedings at the same location as the initial bleeding event.
By day 30 after PCC administration, 22 (22%) deaths were observed (Table 4) , of which 18 were in patients with ICH. The mortality rate in ICH patients was 44% (18 of 41) and in patients with GI bleeding 8% (3 of 36). The cause of death was related to the bleeding event in 13 (59%) of 22 of the patients. None of the deaths were attributed to thrombosis, ie, pulmonary embolism or myocardial infarction. The median duration of hospital stay was 7 days, and 21% of patients was admitted in the ICU for a median of 3 days. 
| Clinical presentation and course
T A B L E 3 Haemostatic efficacy of VKA-associated bleeding events
Total patients N = 100
Adapted assessment of haemostatic efficacy, n/N (%) T A B L E 4 Safety outcomes of VKA-associated bleeding events 
| DISCUSSION
The present multicenter cohort study shows that infusion of PCC was able to achieve effective haemostasis in 68% of patients with VKAassociated bleeding complications based on an adapted assessment of haemostatic efficacy using our surrogate efficacy outcome for ICH patients. In addition, TE complication rates were low and mortality rates rather high within 30 days after PCC administration. Sub-classification of clinical presentation and course of major VKA-associated bleeding showed that two-thirds of patients had a severe clinical presentation, and half also had a severe clinical course, meaning that the bleeding was life-threatening and required elaborate measures to avoid death, could still be fatal after interventions and could lead to permanent disability, or death was unavoidable.
In a previously published randomized controlled trial, PCC was compared to plasma for immediate reversal of VKA-associated major bleedings. 17 In that study, effective haemostasis was achieved in 72% of patients receiving PCC, which is consistent with our findings. An advantage of our cohort study is that we included all consecutive patients with bleeding events in comparison to trial patients that had to fulfill in-and exclusion criteria.
17
The rapid and almost complete INR normalization observed in the current analysis is consistent with findings from previous studies. 3, 17, [24] [25] [26] [27] In addition, the reported TE event rate (5%) is comparable to those from earlier reports (range 3.9-6.2%). 17, 25, 28, 29 The possible association between the administration of PCC and the occurrence of TE complications remains a concern. In most studies, including ours, it is impossible to disentangle the potentially thromboembolic effects of PCC from the effects of cessation of anticoagulation. 27, 29 Finally, the observed mortality rate was 22%. This rate was similar to numbers reported (25%) in a recent systematic review of PCC, 25 but somewhat higher than in other studies (range 5.8-7.8%). 17, 30 The high mortality rate in this study can be explained by the large number of patients included with ICH compared to other studies, reflecting the presence of severe bleeding complications of VKA treatment.
Strengths of the present study include consecutive sampling, the relative homogeneous population of patients with VKA-related bleeding events that were all treated with PCC, the representativeness of the patients from daily practice, the comprehensive and standardized data retrieval on standardized report forms, the use of the extensive predefined criteria for haemostatic efficacy, the evaluation of clinically relevant outcome parameters (INR normalization, thromboembolic complications, and mortality), and the long-term availability and experience with PCC in all national hospitals in the Netherlands.
Some methodological aspects of our study require further comment. First, no repeat CT scan after reversal with PCC was performed in almost 80% of patients with ICH. This is explained by local treatment protocols in which repeat CT imaging is only done in patients with neurological deterioration and not in patients that are neurologically stable or in patients with infaust prognosis who are considered beyond repair. We believe our surrogate outcome to be a valid surrogate for Therefore, these findings need to be interpreted with caution, since they do not represent the total study population. The described INR values after PCC administration might be an over-or underrepresentation of the true INR values for all patients. Finally, 14% of patients were classified as having a minor bleeding. The decision to treat with PCC was at the discretion of the treating physician, and the diagnosis of major or minor bleeding was made in retrospect by chart review.
However, one could speculate that events classified as minor bleeding might not have needed PCC, and including these events could have slightly overestimated the haemostatic efficacy outcome.
Overall, the results from this study support the use of PCC as primary treatment for VKA-associated bleeding events as recommended by recent guidelines. 1, 11, 12 Since we included real-world patients experiencing bleeding complications of VKA treatment, our results are likely to be generalizable to other patients needing PCC for VKAassociated bleeding.
In conclusion, our study assessed clinical outcomes, haemostatic efficacy and INR normalization in patients treated with PCC for VKAassociated bleeding complications. The most frequently observed bleeding was ICH. PCC administration was shown to achieve effective haemostasis in 68% of patients with VKA-associated bleeding. TE complication rates were low, but mortality rates high, due to the large number of patients presenting with ICH. 
AUTHOR CONTRIBUTIONS
